Prime Time for CAR T Cells – OncLive
|
Prime Time for CAR T Cells
OncLive Chimeric antigen receptor (CAR) T cells have hit prime time, with the 2 recent FDA approvals for this class of cell-based therapy. Undoubtedly this option will be a game changer for patients with B-cell malignancies who have only a small number of … |
